Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 23 | 2024 | 225 | 11.990 |
Why?
|
Rheumatic Diseases | 37 | 2024 | 649 | 9.910 |
Why?
|
Antirheumatic Agents | 24 | 2024 | 1365 | 4.590 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 14 | 2023 | 289 | 4.560 |
Why?
|
Autoimmune Diseases | 25 | 2024 | 2238 | 4.200 |
Why?
|
Rheumatology | 18 | 2023 | 615 | 3.270 |
Why?
|
Immunoglobulin G | 33 | 2024 | 4533 | 2.970 |
Why?
|
Peroxidase | 5 | 2023 | 610 | 2.350 |
Why?
|
Kidney Failure, Chronic | 8 | 2024 | 2474 | 2.060 |
Why?
|
Glucocorticoids | 22 | 2024 | 2160 | 2.000 |
Why?
|
Arthritis, Rheumatoid | 16 | 2024 | 3752 | 1.820 |
Why?
|
Biological Products | 9 | 2021 | 912 | 1.770 |
Why?
|
Plasma Cells | 7 | 2023 | 597 | 1.510 |
Why?
|
Vasculitis | 4 | 2023 | 522 | 1.360 |
Why?
|
Myeloblastin | 2 | 2019 | 101 | 1.320 |
Why?
|
Takayasu Arteritis | 3 | 2024 | 105 | 1.080 |
Why?
|
Remission Induction | 10 | 2023 | 2391 | 1.000 |
Why?
|
Pneumonia, Pneumocystis | 2 | 2023 | 242 | 0.980 |
Why?
|
Polyarteritis Nodosa | 2 | 2022 | 70 | 0.940 |
Why?
|
Giant Cell Arteritis | 3 | 2024 | 306 | 0.920 |
Why?
|
Lupus Nephritis | 3 | 2022 | 317 | 0.880 |
Why?
|
Polychondritis, Relapsing | 2 | 2013 | 29 | 0.850 |
Why?
|
Kidney Transplantation | 4 | 2022 | 4218 | 0.810 |
Why?
|
Cyclophosphamide | 9 | 2023 | 2218 | 0.790 |
Why?
|
Retroperitoneal Fibrosis | 2 | 2019 | 42 | 0.790 |
Why?
|
Deltoid Muscle | 1 | 2021 | 18 | 0.790 |
Why?
|
Humans | 166 | 2024 | 760740 | 0.780 |
Why?
|
Receptors, Interleukin-6 | 2 | 2013 | 224 | 0.770 |
Why?
|
Immunosuppressive Agents | 9 | 2023 | 4172 | 0.760 |
Why?
|
Middle Aged | 81 | 2024 | 220603 | 0.750 |
Why?
|
IgG Deficiency | 1 | 2020 | 28 | 0.710 |
Why?
|
Immunoglobulin Isotypes | 1 | 2020 | 158 | 0.680 |
Why?
|
Male | 95 | 2024 | 360402 | 0.680 |
Why?
|
Mikulicz' Disease | 1 | 2019 | 8 | 0.650 |
Why?
|
Immunologic Factors | 9 | 2024 | 1589 | 0.650 |
Why?
|
Female | 96 | 2024 | 392203 | 0.640 |
Why?
|
Dermatomyositis | 1 | 2021 | 258 | 0.620 |
Why?
|
Career Mobility | 1 | 2020 | 259 | 0.610 |
Why?
|
Aortitis | 1 | 2019 | 74 | 0.600 |
Why?
|
Otorhinolaryngologic Diseases | 1 | 2019 | 97 | 0.590 |
Why?
|
Lung Injury | 1 | 2022 | 422 | 0.590 |
Why?
|
Hepatitis B virus | 2 | 2021 | 527 | 0.580 |
Why?
|
Antibody Specificity | 1 | 2019 | 1057 | 0.580 |
Why?
|
Aged | 53 | 2024 | 169092 | 0.580 |
Why?
|
Renal Insufficiency | 1 | 2023 | 808 | 0.570 |
Why?
|
Pandemics | 11 | 2023 | 8652 | 0.570 |
Why?
|
Digestive System Diseases | 1 | 2019 | 151 | 0.570 |
Why?
|
Registries | 15 | 2023 | 8209 | 0.560 |
Why?
|
Coronavirus Infections | 5 | 2020 | 3088 | 0.560 |
Why?
|
Hospitalization | 11 | 2022 | 10708 | 0.560 |
Why?
|
Pneumonia, Viral | 5 | 2020 | 3209 | 0.560 |
Why?
|
Gastrointestinal Agents | 1 | 2021 | 510 | 0.550 |
Why?
|
Azathioprine | 4 | 2023 | 354 | 0.530 |
Why?
|
Hepatitis B, Chronic | 1 | 2020 | 410 | 0.520 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2214 | 0.510 |
Why?
|
Cohort Studies | 20 | 2024 | 41464 | 0.510 |
Why?
|
Respiration, Artificial | 7 | 2022 | 2630 | 0.510 |
Why?
|
Drug Monitoring | 1 | 2021 | 960 | 0.500 |
Why?
|
Orbital Myositis | 2 | 2013 | 25 | 0.500 |
Why?
|
Autoantibodies | 3 | 2020 | 2115 | 0.490 |
Why?
|
Orbital Pseudotumor | 2 | 2013 | 42 | 0.490 |
Why?
|
Adult | 58 | 2024 | 220995 | 0.470 |
Why?
|
Physicians, Women | 1 | 2020 | 509 | 0.470 |
Why?
|
Lung Diseases, Interstitial | 1 | 2023 | 918 | 0.450 |
Why?
|
Lung | 4 | 2021 | 9999 | 0.450 |
Why?
|
Eosinophils | 2 | 2016 | 953 | 0.450 |
Why?
|
Comorbidity | 9 | 2024 | 10507 | 0.430 |
Why?
|
Hypersensitivity | 1 | 2022 | 1167 | 0.410 |
Why?
|
Piperidines | 2 | 2021 | 1655 | 0.410 |
Why?
|
Information Dissemination | 2 | 2020 | 1126 | 0.410 |
Why?
|
Faculty, Medical | 1 | 2020 | 1204 | 0.400 |
Why?
|
Immunity, Cellular | 2 | 2015 | 1550 | 0.390 |
Why?
|
Hypergammaglobulinemia | 1 | 2011 | 71 | 0.390 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 5 | 2015 | 693 | 0.380 |
Why?
|
Meningitis | 1 | 2013 | 217 | 0.380 |
Why?
|
Anti-Infective Agents | 1 | 2019 | 983 | 0.380 |
Why?
|
Trigeminal Nerve Diseases | 1 | 2011 | 49 | 0.370 |
Why?
|
Sex Factors | 4 | 2024 | 10549 | 0.370 |
Why?
|
Lipid Metabolism | 1 | 2019 | 1896 | 0.370 |
Why?
|
Myocardial Infarction | 2 | 2022 | 11458 | 0.370 |
Why?
|
Paraproteinemias | 1 | 2013 | 248 | 0.360 |
Why?
|
Gene Regulatory Networks | 1 | 2019 | 1745 | 0.350 |
Why?
|
Fever | 4 | 2021 | 1618 | 0.340 |
Why?
|
Immune System Diseases | 3 | 2017 | 254 | 0.330 |
Why?
|
Pyrimidines | 2 | 2021 | 3027 | 0.320 |
Why?
|
United States | 19 | 2024 | 72292 | 0.320 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2023 | 2252 | 0.310 |
Why?
|
Disease Progression | 7 | 2023 | 13495 | 0.300 |
Why?
|
Severity of Illness Index | 8 | 2022 | 15829 | 0.300 |
Why?
|
Eye Diseases | 1 | 2013 | 653 | 0.300 |
Why?
|
Computational Biology | 2 | 2023 | 3509 | 0.300 |
Why?
|
Body Composition | 1 | 2017 | 2426 | 0.290 |
Why?
|
Lupus Erythematosus, Systemic | 5 | 2023 | 2152 | 0.290 |
Why?
|
Electronic Health Records | 2 | 2024 | 4810 | 0.280 |
Why?
|
Retrospective Studies | 18 | 2024 | 80583 | 0.280 |
Why?
|
Vaccination | 7 | 2024 | 3370 | 0.280 |
Why?
|
Immunity, Humoral | 2 | 2023 | 600 | 0.270 |
Why?
|
Antibody Formation | 2 | 2021 | 1390 | 0.260 |
Why?
|
Cause of Death | 5 | 2020 | 3683 | 0.260 |
Why?
|
Autoantigens | 3 | 2020 | 888 | 0.260 |
Why?
|
Diagnosis, Differential | 7 | 2021 | 12966 | 0.260 |
Why?
|
Gout | 2 | 2022 | 621 | 0.250 |
Why?
|
Incidence | 7 | 2024 | 21339 | 0.250 |
Why?
|
Prednisone | 4 | 2022 | 1562 | 0.240 |
Why?
|
Hyperesthesia | 1 | 2024 | 23 | 0.230 |
Why?
|
Risk Factors | 15 | 2024 | 74128 | 0.230 |
Why?
|
Psoriasis | 2 | 2023 | 944 | 0.220 |
Why?
|
Massachusetts | 3 | 2021 | 8835 | 0.220 |
Why?
|
Pneumocystis carinii | 1 | 2023 | 72 | 0.210 |
Why?
|
Hospital Mortality | 1 | 2017 | 5292 | 0.210 |
Why?
|
Adenosine Monophosphate | 1 | 2024 | 231 | 0.210 |
Why?
|
Arthritis, Psoriatic | 2 | 2023 | 219 | 0.210 |
Why?
|
Systemic Vasculitis | 1 | 2023 | 36 | 0.210 |
Why?
|
Neoplasms | 3 | 2022 | 22131 | 0.200 |
Why?
|
Databases, Factual | 2 | 2019 | 7963 | 0.200 |
Why?
|
Europe | 2 | 2019 | 3415 | 0.200 |
Why?
|
Alanine | 1 | 2024 | 609 | 0.190 |
Why?
|
Glomerulonephritis, Membranous | 2 | 2020 | 87 | 0.190 |
Why?
|
Leukocyte Count | 2 | 2016 | 1597 | 0.190 |
Why?
|
Recurrence | 5 | 2022 | 8426 | 0.190 |
Why?
|
Proportional Hazards Models | 7 | 2021 | 12448 | 0.190 |
Why?
|
Mycophenolic Acid | 2 | 2020 | 348 | 0.190 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2020 | 1779 | 0.190 |
Why?
|
Oral Ulcer | 1 | 2021 | 96 | 0.180 |
Why?
|
Spirometry | 1 | 2024 | 928 | 0.180 |
Why?
|
Nipecotic Acids | 1 | 2021 | 36 | 0.180 |
Why?
|
Arteritis | 1 | 2023 | 158 | 0.180 |
Why?
|
Informatics | 1 | 2021 | 72 | 0.180 |
Why?
|
Churg-Strauss Syndrome | 1 | 2021 | 75 | 0.180 |
Why?
|
Case-Control Studies | 5 | 2023 | 22153 | 0.170 |
Why?
|
Arthralgia | 2 | 2021 | 461 | 0.170 |
Why?
|
Mobility Limitation | 1 | 2024 | 408 | 0.170 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2022 | 4365 | 0.170 |
Why?
|
Medicare | 4 | 2022 | 6774 | 0.170 |
Why?
|
Insurance Claim Review | 1 | 2024 | 741 | 0.170 |
Why?
|
Methotrexate | 3 | 2023 | 1716 | 0.170 |
Why?
|
Genome-Wide Association Study | 1 | 2019 | 12661 | 0.170 |
Why?
|
Colchicine | 1 | 2021 | 259 | 0.160 |
Why?
|
Myositis | 1 | 2022 | 269 | 0.160 |
Why?
|
Aged, 80 and over | 11 | 2024 | 58919 | 0.160 |
Why?
|
Receptors, Phospholipase A2 | 1 | 2019 | 33 | 0.160 |
Why?
|
Exanthema | 2 | 2021 | 503 | 0.160 |
Why?
|
Drug Resistance, Viral | 1 | 2024 | 861 | 0.160 |
Why?
|
Americas | 1 | 2019 | 110 | 0.160 |
Why?
|
Viruses | 1 | 2023 | 374 | 0.160 |
Why?
|
Antibodies, Viral | 4 | 2024 | 3149 | 0.160 |
Why?
|
Patient Acceptance of Health Care | 2 | 2024 | 3196 | 0.160 |
Why?
|
Treatment Outcome | 11 | 2024 | 64572 | 0.160 |
Why?
|
Blood Sedimentation | 1 | 2019 | 235 | 0.160 |
Why?
|
Lymphoma | 2 | 2017 | 1899 | 0.150 |
Why?
|
Fibrosis | 4 | 2021 | 2047 | 0.150 |
Why?
|
Entropy | 1 | 2019 | 210 | 0.150 |
Why?
|
Health Resources | 1 | 2024 | 934 | 0.150 |
Why?
|
Apolipoprotein A-I | 1 | 2019 | 299 | 0.150 |
Why?
|
Inflammation | 2 | 2024 | 10759 | 0.150 |
Why?
|
Drug Therapy, Combination | 5 | 2021 | 6305 | 0.150 |
Why?
|
Fatigue | 2 | 2023 | 1550 | 0.150 |
Why?
|
Apolipoproteins B | 1 | 2019 | 385 | 0.150 |
Why?
|
Neoplasms, Plasma Cell | 1 | 2017 | 39 | 0.140 |
Why?
|
Asia | 1 | 2019 | 616 | 0.140 |
Why?
|
Scleroderma, Systemic | 1 | 2021 | 344 | 0.140 |
Why?
|
Gastroesophageal Reflux | 1 | 2024 | 821 | 0.140 |
Why?
|
Uncertainty | 1 | 2022 | 752 | 0.140 |
Why?
|
Education, Medical, Graduate | 2 | 2020 | 2373 | 0.140 |
Why?
|
Fatal Outcome | 1 | 2021 | 1835 | 0.140 |
Why?
|
Temporal Arteries | 1 | 2018 | 154 | 0.140 |
Why?
|
Education, Distance | 1 | 2020 | 259 | 0.140 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2017 | 99 | 0.140 |
Why?
|
Waiting Lists | 2 | 2019 | 764 | 0.140 |
Why?
|
Interinstitutional Relations | 1 | 2018 | 236 | 0.140 |
Why?
|
Subclavian Artery | 1 | 2017 | 133 | 0.140 |
Why?
|
Odds Ratio | 4 | 2021 | 9644 | 0.130 |
Why?
|
Logistic Models | 3 | 2020 | 13248 | 0.130 |
Why?
|
Galectin 3 | 1 | 2018 | 240 | 0.130 |
Why?
|
Arthritis, Infectious | 1 | 2020 | 347 | 0.130 |
Why?
|
Antibodies, Monoclonal | 4 | 2024 | 9171 | 0.130 |
Why?
|
Accidental Falls | 1 | 2024 | 1067 | 0.130 |
Why?
|
Hepatitis B | 1 | 2021 | 704 | 0.130 |
Why?
|
Lymphocyte Count | 2 | 2016 | 777 | 0.130 |
Why?
|
Age Factors | 3 | 2024 | 18381 | 0.130 |
Why?
|
Neutropenia | 1 | 2020 | 885 | 0.130 |
Why?
|
Schools | 2 | 2022 | 1483 | 0.130 |
Why?
|
Aniline Compounds | 1 | 2021 | 1068 | 0.120 |
Why?
|
Testis | 1 | 2018 | 792 | 0.120 |
Why?
|
Physicians | 2 | 2023 | 4583 | 0.120 |
Why?
|
Cardiovascular Agents | 1 | 2021 | 840 | 0.120 |
Why?
|
Commerce | 1 | 2020 | 608 | 0.120 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 26065 | 0.120 |
Why?
|
Flow Cytometry | 2 | 2015 | 5863 | 0.120 |
Why?
|
Antibody-Producing Cells | 1 | 2014 | 140 | 0.110 |
Why?
|
Cytoplasm | 1 | 2019 | 1503 | 0.110 |
Why?
|
China | 1 | 2020 | 2374 | 0.110 |
Why?
|
B-Lymphocytes | 3 | 2023 | 4745 | 0.110 |
Why?
|
Phenotype | 2 | 2024 | 16572 | 0.110 |
Why?
|
Biomedical Research | 2 | 2021 | 3426 | 0.110 |
Why?
|
Coronary Aneurysm | 1 | 2016 | 232 | 0.110 |
Why?
|
International Cooperation | 1 | 2020 | 1422 | 0.110 |
Why?
|
Antimalarials | 1 | 2020 | 907 | 0.110 |
Why?
|
Lymphocytosis | 1 | 2014 | 121 | 0.110 |
Why?
|
Immunoglobulin E | 2 | 2018 | 1502 | 0.110 |
Why?
|
Dacryocystitis | 1 | 2013 | 68 | 0.110 |
Why?
|
Prevalence | 2 | 2023 | 15702 | 0.110 |
Why?
|
Research Personnel | 1 | 2018 | 588 | 0.110 |
Why?
|
Arterial Occlusive Diseases | 1 | 2017 | 748 | 0.110 |
Why?
|
Cholesterol, HDL | 1 | 2019 | 1810 | 0.100 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 3798 | 0.100 |
Why?
|
Myofibroblasts | 1 | 2014 | 223 | 0.100 |
Why?
|
Risk Assessment | 3 | 2023 | 23974 | 0.100 |
Why?
|
Mentors | 1 | 2018 | 661 | 0.100 |
Why?
|
Myocardial Ischemia | 1 | 2023 | 2110 | 0.100 |
Why?
|
Th2 Cells | 1 | 2017 | 1056 | 0.100 |
Why?
|
Antiviral Agents | 1 | 2024 | 3037 | 0.100 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 14649 | 0.100 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2013 | 178 | 0.100 |
Why?
|
Antigens, CD | 2 | 2020 | 3998 | 0.100 |
Why?
|
Needs Assessment | 1 | 2018 | 1139 | 0.100 |
Why?
|
Cardiovascular Diseases | 5 | 2020 | 15498 | 0.100 |
Why?
|
Data Collection | 1 | 2021 | 3316 | 0.090 |
Why?
|
Hypertrophy | 1 | 2013 | 560 | 0.090 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2016 | 536 | 0.090 |
Why?
|
Health Care Costs | 1 | 2024 | 3238 | 0.090 |
Why?
|
Leadership | 1 | 2020 | 1385 | 0.090 |
Why?
|
Retreatment | 1 | 2013 | 596 | 0.090 |
Why?
|
Cardiomyopathies | 1 | 2023 | 1948 | 0.090 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20077 | 0.090 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 2270 | 0.090 |
Why?
|
Premature Birth | 1 | 2023 | 1782 | 0.090 |
Why?
|
Exophthalmos | 1 | 2011 | 97 | 0.090 |
Why?
|
Quality of Life | 2 | 2023 | 13359 | 0.090 |
Why?
|
Lumbar Vertebrae | 1 | 2020 | 1874 | 0.090 |
Why?
|
Cholesterol | 1 | 2019 | 2902 | 0.090 |
Why?
|
Multivariate Analysis | 2 | 2020 | 12043 | 0.090 |
Why?
|
Interleukin-12 | 2 | 2023 | 577 | 0.090 |
Why?
|
Cholesterol, LDL | 1 | 2019 | 2378 | 0.090 |
Why?
|
Consensus | 1 | 2019 | 3117 | 0.090 |
Why?
|
Predictive Value of Tests | 2 | 2024 | 15250 | 0.080 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2021 | 2423 | 0.080 |
Why?
|
Medicaid | 2 | 2021 | 2814 | 0.080 |
Why?
|
Kidney Diseases | 1 | 2020 | 2090 | 0.080 |
Why?
|
Kidney | 2 | 2023 | 7044 | 0.080 |
Why?
|
Sepsis | 2 | 2020 | 2585 | 0.080 |
Why?
|
Mesenchymal Stem Cells | 1 | 2020 | 1642 | 0.080 |
Why?
|
Chest Pain | 1 | 2016 | 1091 | 0.080 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39062 | 0.080 |
Why?
|
Software | 1 | 2023 | 4432 | 0.080 |
Why?
|
RNA, Messenger | 1 | 2023 | 12759 | 0.080 |
Why?
|
Lipids | 1 | 2019 | 3332 | 0.080 |
Why?
|
Internet | 1 | 2021 | 3094 | 0.080 |
Why?
|
Young Adult | 8 | 2021 | 59191 | 0.080 |
Why?
|
Drug Hypersensitivity | 1 | 2017 | 917 | 0.070 |
Why?
|
Vascular Diseases | 1 | 2016 | 1159 | 0.070 |
Why?
|
Mental Health | 1 | 2022 | 3253 | 0.070 |
Why?
|
Societies, Medical | 1 | 2019 | 3901 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 4 | 2021 | 20556 | 0.070 |
Why?
|
Smoking | 1 | 2024 | 9054 | 0.070 |
Why?
|
Health Expenditures | 1 | 2020 | 2363 | 0.070 |
Why?
|
Genomics | 1 | 2023 | 5822 | 0.070 |
Why?
|
Retroperitoneal Space | 2 | 2018 | 170 | 0.070 |
Why?
|
Hydroxychloroquine | 2 | 2020 | 426 | 0.070 |
Why?
|
Prospective Studies | 7 | 2024 | 54364 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6473 | 0.060 |
Why?
|
Adolescent | 9 | 2023 | 88247 | 0.060 |
Why?
|
Apoptosis | 1 | 2020 | 9476 | 0.060 |
Why?
|
Coronary Artery Disease | 1 | 2023 | 6403 | 0.050 |
Why?
|
Urban Health | 1 | 2005 | 532 | 0.050 |
Why?
|
Complement Activation | 1 | 2024 | 445 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10203 | 0.050 |
Why?
|
Endemic Diseases | 1 | 2023 | 191 | 0.050 |
Why?
|
Knee | 1 | 2024 | 279 | 0.050 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2022 | 63 | 0.050 |
Why?
|
Depression | 1 | 2022 | 8132 | 0.050 |
Why?
|
Epitopes, B-Lymphocyte | 1 | 2022 | 82 | 0.050 |
Why?
|
Prognosis | 2 | 2024 | 29601 | 0.050 |
Why?
|
Cooperative Behavior | 2 | 2021 | 1505 | 0.050 |
Why?
|
Vaccines, Subunit | 1 | 2022 | 158 | 0.050 |
Why?
|
Homicide | 1 | 2005 | 294 | 0.050 |
Why?
|
Asthma | 1 | 2021 | 6234 | 0.050 |
Why?
|
Touch | 1 | 2024 | 310 | 0.050 |
Why?
|
Ritonavir | 1 | 2023 | 329 | 0.050 |
Why?
|
Pilot Projects | 3 | 2023 | 8619 | 0.050 |
Why?
|
Complement System Proteins | 1 | 2024 | 734 | 0.050 |
Why?
|
Prednisolone | 1 | 2022 | 324 | 0.050 |
Why?
|
Coronary Vessels | 2 | 2023 | 3095 | 0.050 |
Why?
|
Vital Capacity | 1 | 2024 | 971 | 0.050 |
Why?
|
Students | 2 | 2022 | 1736 | 0.050 |
Why?
|
Survival Rate | 1 | 2015 | 12719 | 0.050 |
Why?
|
Wisconsin | 1 | 2021 | 122 | 0.050 |
Why?
|
Bacteroidetes | 1 | 2021 | 83 | 0.050 |
Why?
|
Filgrastim | 1 | 2020 | 132 | 0.050 |
Why?
|
Nephrosis, Lipoid | 1 | 2020 | 45 | 0.040 |
Why?
|
Hematologic Agents | 1 | 2020 | 40 | 0.040 |
Why?
|
Spondylarthropathies | 1 | 2020 | 14 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13635 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2023 | 424 | 0.040 |
Why?
|
Foot | 1 | 2024 | 575 | 0.040 |
Why?
|
Receptors, Fc | 1 | 2023 | 534 | 0.040 |
Why?
|
Quarantine | 1 | 2022 | 182 | 0.040 |
Why?
|
Azetidines | 1 | 2020 | 142 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4570 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2023 | 793 | 0.040 |
Why?
|
Environment | 1 | 2005 | 1123 | 0.040 |
Why?
|
Chloroquine | 1 | 2020 | 275 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 612 | 0.040 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 299 | 0.040 |
Why?
|
Forced Expiratory Volume | 1 | 2024 | 1814 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 199 | 0.040 |
Why?
|
Toll-Like Receptor 4 | 1 | 2022 | 578 | 0.040 |
Why?
|
Renal Replacement Therapy | 1 | 2021 | 281 | 0.040 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2022 | 825 | 0.040 |
Why?
|
Hand | 1 | 2024 | 902 | 0.040 |
Why?
|
Immunosorbent Techniques | 1 | 2018 | 174 | 0.040 |
Why?
|
Masks | 1 | 2021 | 208 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 14024 | 0.040 |
Why?
|
Coronary Angiography | 2 | 2023 | 4470 | 0.040 |
Why?
|
Virulence | 1 | 2022 | 1299 | 0.040 |
Why?
|
Microcirculation | 1 | 2023 | 1272 | 0.040 |
Why?
|
Time Factors | 2 | 2018 | 39908 | 0.040 |
Why?
|
Posterior Leukoencephalopathy Syndrome | 1 | 2018 | 49 | 0.040 |
Why?
|
Confusion | 1 | 2020 | 278 | 0.040 |
Why?
|
Muscular Diseases | 1 | 2022 | 552 | 0.040 |
Why?
|
Asymptomatic Diseases | 1 | 2020 | 587 | 0.040 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 2020 | 335 | 0.040 |
Why?
|
Purines | 1 | 2020 | 606 | 0.040 |
Why?
|
Intensive Care Units | 2 | 2021 | 3743 | 0.040 |
Why?
|
Interleukin-10 | 1 | 2022 | 1171 | 0.030 |
Why?
|
Leukocytosis | 1 | 2018 | 251 | 0.030 |
Why?
|
Hematuria | 1 | 2018 | 232 | 0.030 |
Why?
|
Thrombocytosis | 1 | 2017 | 88 | 0.030 |
Why?
|
Coronary Circulation | 1 | 2023 | 1569 | 0.030 |
Why?
|
Species Specificity | 1 | 2021 | 2410 | 0.030 |
Why?
|
Pregnant Women | 1 | 2021 | 567 | 0.030 |
Why?
|
Epididymis | 1 | 2018 | 227 | 0.030 |
Why?
|
Immunomodulation | 1 | 2020 | 548 | 0.030 |
Why?
|
Biological Evolution | 1 | 2022 | 1070 | 0.030 |
Why?
|
Aorta | 1 | 2024 | 2041 | 0.030 |
Why?
|
Submandibular Gland | 1 | 2016 | 87 | 0.030 |
Why?
|
Kinetics | 1 | 2024 | 6370 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2020 | 664 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2022 | 2079 | 0.030 |
Why?
|
Canada | 1 | 2021 | 2120 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2023 | 1742 | 0.030 |
Why?
|
Curriculum | 2 | 2020 | 3739 | 0.030 |
Why?
|
Erythema | 1 | 2017 | 262 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2022 | 1888 | 0.030 |
Why?
|
Drugs, Generic | 1 | 2021 | 448 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2005 | 2092 | 0.030 |
Why?
|
Lymphocyte Depletion | 1 | 2017 | 601 | 0.030 |
Why?
|
Lymphocyte Activation | 2 | 2018 | 5463 | 0.030 |
Why?
|
Internationality | 1 | 2021 | 1000 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2018 | 850 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2020 | 858 | 0.030 |
Why?
|
Sarcoidosis | 1 | 2020 | 520 | 0.030 |
Why?
|
Nasal Septum | 1 | 2016 | 130 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2022 | 1962 | 0.030 |
Why?
|
Antibody Diversity | 1 | 2014 | 72 | 0.030 |
Why?
|
Biopsy | 2 | 2017 | 6763 | 0.030 |
Why?
|
Somatic Hypermutation, Immunoglobulin | 1 | 2014 | 101 | 0.030 |
Why?
|
Drug Approval | 1 | 2021 | 812 | 0.030 |
Why?
|
Pancreas | 1 | 2020 | 1691 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2021 | 1718 | 0.030 |
Why?
|
Arthroscopy | 1 | 2020 | 969 | 0.030 |
Why?
|
New York City | 2 | 2005 | 731 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2023 | 2896 | 0.030 |
Why?
|
Depressive Disorder | 1 | 2005 | 3735 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1661 | 0.030 |
Why?
|
Prostate | 1 | 2020 | 1773 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2023 | 26183 | 0.020 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2017 | 974 | 0.020 |
Why?
|
Bacteria | 1 | 2023 | 2192 | 0.020 |
Why?
|
Program Development | 1 | 2018 | 1293 | 0.020 |
Why?
|
Anti-Bacterial Agents | 2 | 2020 | 7403 | 0.020 |
Why?
|
Influenza, Human | 1 | 2023 | 1521 | 0.020 |
Why?
|
Travel | 1 | 2017 | 796 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2018 | 2189 | 0.020 |
Why?
|
Sulfonamides | 1 | 2020 | 1977 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2020 | 36401 | 0.020 |
Why?
|
Clone Cells | 1 | 2014 | 1657 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2018 | 10429 | 0.020 |
Why?
|
Magnetic Resonance Angiography | 1 | 2017 | 1431 | 0.020 |
Why?
|
Pregnancy | 2 | 2023 | 29869 | 0.020 |
Why?
|
Rural Population | 1 | 2021 | 2277 | 0.020 |
Why?
|
Pyrazoles | 1 | 2020 | 2008 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4845 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2020 | 3705 | 0.020 |
Why?
|
Anaphylaxis | 1 | 2017 | 757 | 0.020 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 3204 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2017 | 1797 | 0.020 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1923 | 0.020 |
Why?
|
Outpatients | 1 | 2017 | 1596 | 0.020 |
Why?
|
Skin Diseases | 1 | 2017 | 1094 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2018 | 6520 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2005 | 4416 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 1202 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9313 | 0.020 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1866 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2024 | 14599 | 0.020 |
Why?
|
Anemia | 1 | 2017 | 1504 | 0.020 |
Why?
|
Public Health | 1 | 2021 | 2671 | 0.020 |
Why?
|
Qualitative Research | 1 | 2018 | 3017 | 0.020 |
Why?
|
Research Design | 1 | 2022 | 6174 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2018 | 3820 | 0.020 |
Why?
|
Survival Analysis | 1 | 2019 | 10072 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2812 | 0.020 |
Why?
|
Ultrasonography | 1 | 2018 | 5965 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2016 | 3461 | 0.010 |
Why?
|
Coronary Disease | 1 | 2019 | 5911 | 0.010 |
Why?
|
Child | 2 | 2023 | 80089 | 0.010 |
Why?
|
Pain | 1 | 2018 | 5062 | 0.010 |
Why?
|
Electrocardiography | 1 | 2016 | 6346 | 0.010 |
Why?
|
Cytokines | 1 | 2016 | 7373 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11069 | 0.010 |
Why?
|
Demography | 1 | 2005 | 1643 | 0.010 |
Why?
|
Mutation | 1 | 2024 | 30015 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2017 | 5334 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2017 | 18220 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 42193 | 0.010 |
Why?
|
Animals | 2 | 2022 | 168202 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23415 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2005 | 7805 | 0.010 |
Why?
|
Mice | 1 | 2017 | 81368 | 0.010 |
Why?
|